What's in GE HealthCare Technologies's pipeline?

GE HealthCare Technologies has 28 drugs in our index: 18 marketed, 0 filed, 7 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with GE HealthCare Technologies's portfolio?

Top competitors by shared drug class: , Bayer, Bracco Diagnostics, Inc, Guerbet, Bracco.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ge-healthcare.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

GE HealthCare Technologies — Portfolio Competitive Intelligence Brief

GE HealthCare Technologies (GEHC) pipeline: 18 marketed, 0 filed, 7 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

GEHC (NASDAQ) 18 marketed 0 filed 7 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cerianna	FLUOROESTRADIOL F-18	marketed	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	Other	2020-01-01
Vizamyl	Flutemetamol (18F)	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	Immunology	2013-01-01
Vizamyl	FLUTEMETAMOL	marketed	Radioactive Diagnostic Agent [EPC]		Immunology	2013-01-01
Adreview	iobenguane (123I)	marketed	Radioactive Diagnostic Agent		Oncology	2008-01-01
Myoview	TECHNETIUM TC 99M TETROFOSMIN	marketed	Radioactive Diagnostic Agent		Cardiovascular	1996-01-01
Visipaque 270	IODIXANOL	marketed	Radiographic Contrast Agent		Hematology	1996-01-01
Omniscan	GADODIAMIDE	marketed	Paramagnetic Contrast Agent [EPC]		Other	1993-01-01
Ceretec	TECHNETIUM TC 99M EXAMETAZIME	marketed	Radioactive Diagnostic Agent [EPC]		Other	1988-01-01
Omnipaque 180	IOHEXOL	marketed	Radiographic Contrast Agent [EPC]		Hematology	1985-01-01
Metrizoate	METRIZOIC ACID	marketed	Radiographic Contrast Agent		Other	1973-01-01
Clariscan	Clariscan	marketed			Other
Iopamidol 300-Arm 2	Iopamidol 300-Arm 2	marketed

Therapeutic area mix

Other · 7
Cardiovascular · 6
Oncology · 3
Hematology · 2
Diagnostic Imaging · 2
Immunology · 2
Radiology · 1
Diagnostic Imaging / Radiology · 1
Imaging · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2028-09-16 — Vizamyl · 8916131 · US

Competitive overlap (companies sharing drug classes)

· 3 shared drug classes
Bayer · 3 shared drug classes
Bracco Diagnostics, Inc · 3 shared drug classes
Guerbet · 2 shared drug classes
Bracco · 2 shared drug classes
Blue Earth Diagnostics Ltd · 1 shared drug class
Blue Earth · 1 shared drug class
Acusphere · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GE HealthCare Technologies:

Cite this brief

Drug Landscape (2026). GE HealthCare Technologies — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ge-healthcare. Accessed 2026-05-16.